The HARMONY Alliance uses Big Data technologies to improve the treatment of blood cancers i.e. Hematologic Malignancies. These are cancers that affect the blood and lymphatic system.
Answering key outstanding questions
In recent decades, diagnosis and treatment of Hematologic Malignancies have substantially improved, but many remain incurable. The key outstanding questions in this field can only be answered by studying large numbers of patients. Therefore, the HARMONY Alliance has developed a unique research infrastructure to facilitate Big Data research in the field of Hematologic Malignancies.
Sharing data, exploration tools and knowledge
The HARMONY Big Data Platform assembles harmonized clinical data from over 179,000 European blood cancer patients (update March 2024). The associated data processing pipeline ensures data safety and quality, as well as patient privacy. The HARMONY Alliance has developed sophisticated data analytic tools, allowing scientists to answer research questions that cannot be addressed with other methods.
Click on the images or links below and listen to our partners sharing their vision and experiences.
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
